18 June 2013
Keywords: spectrum, cell, therapeutics, form, jv, projected, expansion
Article | 08 December 2008
The USA's Spectrum Pharmaceuticals and Cell Therapeutics have formed a 50/50 joint venture to market Zevalin ([90Y]-ibritumomab tiuxetan) in
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
15 December 2008
1 December 2008
17 June 2013
© 2013 thepharmaletter.com